老年B细胞淋巴瘤疗效及安全性分析  

The curative effects and security of elderly patients with B-cell non- Hodgkin lymphoma

作　　者：唐曦[1] 张洪娣[2] 曾晓颖[1] 陈玺[1] 王静文[1] 

机构地区：[1]复旦大学附属华东医院肿瘤科,上海市200040 [2]复旦大学附属华东医院血液科,上海市200040

出　　处：《老年医学与保健》2010年第4期241-244,共4页Geriatrics & Health Care

摘　　要：目的回顾性分析B细胞淋巴瘤老年患者与中青年患者的疗效和安全性。方法初发的B细胞淋巴瘤老年患者33例与中青年患者30例，采用类CHOP或类RCHOP的3周方案进行治疗，至少6个疗程，对两组的疗效及不良事件进行比较。结果老年组与中青年组疗效比较，两组完全缓解与部分缓解无统计学意义。老年组出现的不良事件包括糖耐量受损、肾功能异常、肝功能异常、急性左心功能衰竭和乙肝病毒激活，均高于中青年组。结论最优化的CHOP或RCHOP个体化治疗方案，来提高老年淋巴瘤患者的疗效及治疗耐受性。objective To analyze the curative effects and safety of elderly and middle-aged patients with B-cell non- Hodgkin lymphoma retrospectively. Methods Untreated B-cell non- Hodgkin lymphoma patients in groups of elderly （n=33） and middle-aged （n=30） underwent minimum six cycles of classical CHOP or RCHOP on the basis of 3 weeks per cycle. The curative effects and safety of the two groups were compared. Results There was no statistical difference between the two groups in CR and PR. More adverse events markedly occurred in elderly group than those of middle-aged group in impaired glucose tolerance, renal function abnormal, dysfunction of liver, heart failure and activating HBV. Conclusion The most optimal individual treatment of CHOP or RCHOP may improve the curative effects and safety of elderly patients with B-cell non- Hodgkin lymphoma.

关 键 词：非霍奇金淋巴瘤 老年 疗效 不良事件 

分 类 号：R733.41[医药卫生—肿瘤]